![Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fff123e1eaa7eaf63feb07ce7031d4f0f838a8e4/7-Table2-1.png)
Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar
![Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40291-021-00525-7/MediaObjects/40291_2021_525_Fig1_HTML.png)
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy
![Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/4-Table3-1.png)
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/2-Table1-1.png)
Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer](https://www.mdpi.com/ijms/ijms-21-07661/article_deploy/html/images/ijms-21-07661-g005.png)
IJMS | Free Full-Text | Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer
![Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/3-Table2-1.png)
Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
![Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study](https://www.sgo-iasgo.com/img/articles/mahmoud-al-balas-img1.jpg)
Biological Characteristics of Breast Cancer among Jordanian Women: A retrospective Single Center Cohort Study
![Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fmodpathol.2013.153/MediaObjects/41379_2014_Article_BFmodpathol2013153_Fig1_HTML.jpg)
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig4_HTML.jpg)
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![PinPointcases - UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women PinPointcases - UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women](https://ppcp.mirrorsmed.org/uploads/ckeditor/8688427636d2b8ff5dac2d7412c285d9a390cff7.png)
PinPointcases - UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
![The definition of subgroups in luminal A/B. (A) Subgroups of luminal... | Download Scientific Diagram The definition of subgroups in luminal A/B. (A) Subgroups of luminal... | Download Scientific Diagram](https://www.researchgate.net/publication/364665400/figure/fig2/AS:11431281092267072@1666781909868/The-definition-of-subgroups-in-luminal-A-B-A-Subgroups-of-luminal-A-B-B-Survival.png)
The definition of subgroups in luminal A/B. (A) Subgroups of luminal... | Download Scientific Diagram
![Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0007455115312169-gr1.jpg)